Cargando…

Tolerance to rat monoclonal antibodies. Implications for serotherapy

The antiglobulin response is a major complication of mAb therapy. It has been suggested that, in clinical practice, this might be avoided by using human or chimeric mAbs, or by prior induction of tolerance to the therapeutic mAb. In this study, we show that it is possible to induce tolerance in mice...

Descripción completa

Detalles Bibliográficos
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1986
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2188130/
https://www.ncbi.nlm.nih.gov/pubmed/3486938
_version_ 1782146335982485504
collection PubMed
description The antiglobulin response is a major complication of mAb therapy. It has been suggested that, in clinical practice, this might be avoided by using human or chimeric mAbs, or by prior induction of tolerance to the therapeutic mAb. In this study, we show that it is possible to induce tolerance in mice to the constant regions of rat IgG2b mAbs by both classical deaggregation methods and by anti-L3T4 mAb therapy. Mice tolerant to IgG2b constant region determinants failed to make an antiglobulin response when immunized with a number of mAbs of the same isotype that had no binding specificity for mouse cells, but produced vigorous antiidiotypic responses to cell-binding mAbs. Binding of antibodies to hemopoietic cells rends their idiotypic determinants major immunogens even in the presence of tolerance to constant region epitopes. These findings suggest that the use of human or chimeric mAbs will not be sufficient to eliminate the antiglobulin response, and that additional methods need to be investigated.
format Text
id pubmed-2188130
institution National Center for Biotechnology Information
language English
publishDate 1986
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21881302008-04-17 Tolerance to rat monoclonal antibodies. Implications for serotherapy J Exp Med Articles The antiglobulin response is a major complication of mAb therapy. It has been suggested that, in clinical practice, this might be avoided by using human or chimeric mAbs, or by prior induction of tolerance to the therapeutic mAb. In this study, we show that it is possible to induce tolerance in mice to the constant regions of rat IgG2b mAbs by both classical deaggregation methods and by anti-L3T4 mAb therapy. Mice tolerant to IgG2b constant region determinants failed to make an antiglobulin response when immunized with a number of mAbs of the same isotype that had no binding specificity for mouse cells, but produced vigorous antiidiotypic responses to cell-binding mAbs. Binding of antibodies to hemopoietic cells rends their idiotypic determinants major immunogens even in the presence of tolerance to constant region epitopes. These findings suggest that the use of human or chimeric mAbs will not be sufficient to eliminate the antiglobulin response, and that additional methods need to be investigated. The Rockefeller University Press 1986-06-01 /pmc/articles/PMC2188130/ /pubmed/3486938 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Articles
Tolerance to rat monoclonal antibodies. Implications for serotherapy
title Tolerance to rat monoclonal antibodies. Implications for serotherapy
title_full Tolerance to rat monoclonal antibodies. Implications for serotherapy
title_fullStr Tolerance to rat monoclonal antibodies. Implications for serotherapy
title_full_unstemmed Tolerance to rat monoclonal antibodies. Implications for serotherapy
title_short Tolerance to rat monoclonal antibodies. Implications for serotherapy
title_sort tolerance to rat monoclonal antibodies. implications for serotherapy
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2188130/
https://www.ncbi.nlm.nih.gov/pubmed/3486938